To assess the sensitivity and accuracy of diffusion magnetic resonance imaging (MRI), including diffusion-weighted imaging (DWI) metrics, in identifying early-stage changes in brain white matter related to various white matter diseases.
Adults aged 18-80 years.
Clinical suspicion of early-stage white matter disease.
No prior diagnosis of significant neurological disorders (e.g., stroke, brain tumors).
Ability to provide informed consent.
Pregnancy or breastfeeding.
Contraindications for magnetic resonance imaging (MRI) (e.g., metal implants, pacemakers).
Severe psychiatric or cognitive impairment that prevents participation.
Control Group: Healthy individuals without any clinical history of neurological diseases, matched by age and sex to the patient cohort.